Hession M, Blum R, Podrid P J, Lampert S, Stein J, Lown B
J Am Coll Cardiol. 1986 Feb;7(2):338-43. doi: 10.1016/s0735-1097(86)80502-2.
Mexiletine and tocainide were administered to 79 patients to determine whether the response to one of these drugs would predict the effect of the other. In 57 patients, the two agents were evaluated noninvasively with monitoring and exercise testing, and efficacy was judged by the suppression of spontaneous ventricular arrhythmia. In the remaining 22 patients, electrophysiologic testing was performed and efficacy was defined as the inability to induce more than two repetitive ventricular premature beats. An equal number of patients responded to mexiletine and tocainide (38 versus 39%). However, in only 42 patients (53%) were the results concordant. There was no difference in concordance when the results were analyzed by method of drug evaluation, left ventricular ejection fraction or etiology of presenting arrhythmia. It is concluded that mexiletine and tocainide have different clinical effects and must be evaluated individually.
对79例患者使用了美西律和妥卡尼，以确定对其中一种药物的反应是否能预测另一种药物的效果。在57例患者中，通过监测和运动试验对这两种药物进行了非侵入性评估，疗效通过抑制自发性室性心律失常来判断。在其余22例患者中，进行了电生理测试，疗效定义为不能诱发超过两次重复性室性早搏。对美西律和妥卡尼有反应的患者数量相等（分别为38%和39%）。然而，只有42例患者（53%）的结果一致。当按药物评估方法、左心室射血分数或出现心律失常的病因分析结果时，一致性没有差异。得出的结论是，美西律和妥卡尼有不同的临床效果，必须分别进行评估。
